Wells Fargo Says To Avoid This Investment and Buy US Stocks Instead — Should You Invest?
In a recent note to investors, Wells Fargo analysts mentioned that they recommended avoiding emerging market equities right now.
Trending Now:
Read Next:
Since the massive bank holds a weighty opinion, it's worth digging into their suggestion. GOBankingRates unpacks Wells Fargo's recommendation and what that means for your portfolio.
Investing in emerging markets allows investors to diversify their portfolio beyond U.S. stocks. While you can target specific emerging markets, like India or Indonesia, opting to purchase an index fund focused on a broad swath of emerging markets can give you some exposure across multiple economies with minimal effort on your part.
For example, the MSCI Emerging Markets index offers a popular way for U.S.-based investors to add exposure to emerging markets to their portfolio. In the last year, the MSCI Emerging Market Index saw a net return of 13.04%, which is significantly higher than the S&P 500, which saw a slight decline.
While you might think that the outperformance of the MSCI Emerging Market Index over the S&P 500 would warrant investing more heavily in emerging markets, the opposite is true in Wells Fargo's opinion. Since the MSCI Emerging Market Index did so well in the last year, the analysts recognize that many investors who had invested in emerging markets will have seen their portfolio's composition change over the last year, with perhaps more weight in emerging markets than they would like.
Explore More:
The possible portfolio imbalance, with too much money invested in emerging markets and not enough in U.S. stocks, could represent a problem for some investors. Additionally, Wells Fargo remains unconvinced it's a good idea to stay so heavily weighted in favor of emerging markets.
The note pointed to the structural risks of emerging markets, including 'political and economic instability, corporate governance concerns, variable regulatory risks, as well as China's excessive debt, slumping property sector, and slowing growth.'
All of this to say, Wells Fargo's note encouraged investors to rebalance their portfolios more heavily toward U.S. stocks instead of emerging markets.
In the statement, Wells Fargo said, 'we favor reallocating to U.S. Large Cap, U.S. Mid Cap, or Developed Market (DM) ex-U.S. Equities to maintain overall equity exposure.'
Investors heavily weighted toward emerging markets might sell off some of those investments in order to purchase U.S. stocks. For example, you might sell some of your stake in the MSCI Emerging Markets index in order to buy more in a fund tied to the S&P 500.
If building and managing your own investment portfolio, the right strategy varies based on your interests, skill level and time commitment. For investors with significant time and the patience to monitor the constant turns of the stock market, actively managing it could be a good idea.
But if you are looking for a more hands-off approach with a long-term vision in mind, consider buying and holding low-cost index funds. As you buy and hold index funds for the long term, you can make big-picture changes to your portfolio, like adjusting toward or away from emerging markets occasionally. But, in general, you'll allow the investments to hopefully grow in value over the long term.
Wells Fargo is suggesting that investors shift away from emerging markets toward U.S. stocks. For some investors, the shift could make sense. For others, following through on this change wouldn't align with their investment goals. Take the time to decide what's best for your situation before making any changes to your portfolio.
More From GOBankingRates
10 Cars That Outlast the Average Vehicle
This article originally appeared on GOBankingRates.com: Wells Fargo Says To Avoid This Investment and Buy US Stocks Instead — Should You Invest?
Inicia sesión para acceder a tu portafolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Insiders own 31% of CSP Inc. (NASDAQ:CSPI) shares but retail investors control 42% of the company
The considerable ownership by retail investors in CSP indicates that they collectively have a greater say in management and business strategy A total of 13 investors have a majority stake in the company with 50% ownership Insiders have been buying lately This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. To get a sense of who is truly in control of CSP Inc. (NASDAQ:CSPI), it is important to understand the ownership structure of the business. The group holding the most number of shares in the company, around 42% to be precise, is retail investors. In other words, the group stands to gain the most (or lose the most) from their investment into the company. And individual insiders on the other hand have a 31% ownership in the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Let's take a closer look to see what the different types of shareholders can tell us about CSP. View our latest analysis for CSP Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. As you can see, institutional investors have a fair amount of stake in CSP. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at CSP's earnings history below. Of course, the future is what really matters. We note that hedge funds don't have a meaningful investment in CSP. Our data shows that Joseph Nerges is the largest shareholder with 14% of shares outstanding. For context, the second largest shareholder holds about 8.1% of the shares outstanding, followed by an ownership of 7.1% by the third-largest shareholder. Victor Dellovo, who is the second-largest shareholder, also happens to hold the title of Chief Executive Officer. After doing some more digging, we found that the top 13 have the combined ownership of 50% in the company, suggesting that no single shareholder has significant control over the company. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. As far as we can tell there isn't analyst coverage of the company, so it is probably flying under the radar. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Our information suggests that insiders maintain a significant holding in CSP Inc.. It has a market capitalization of just US$106m, and insiders have US$33m worth of shares in their own names. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling. The general public, who are usually individual investors, hold a 42% stake in CSP. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. While it is well worth considering the different groups that own a company, there are other factors that are even more important. Many find it useful to take an in depth look at how a company has performed in the past. You can access this detailed graph of past earnings, revenue and cash flow. If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, backed by strong financial data. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
35 minutes ago
- Yahoo
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Are Analysts Optimistic?
Phathom Pharmaceuticals, Inc. () is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company's loss has recently broadened since it announced a US$334m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$346m, moving it further away from breakeven. Many investors are wondering about the rate at which Phathom Pharmaceuticals will turn a profit, with the big question being 'when will the company breakeven?' We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Consensus from 8 of the American Pharmaceuticals analysts is that Phathom Pharmaceuticals is on the verge of breakeven. They expect the company to post a final loss in 2026, before turning a profit of US$95m in 2027. Therefore, the company is expected to breakeven roughly 2 years from today. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 68%, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict. We're not going to go through company-specific developments for Phathom Pharmaceuticals given that this is a high-level summary, however, take into account that generally pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment. View our latest analysis for Phathom Pharmaceuticals Before we wrap up, there's one issue worth mentioning. Phathom Pharmaceuticals currently has negative equity on its balance sheet. This can sometimes arise from accounting methods used to deal with accumulated losses from prior years, which are viewed as liabilities carried forward until it cancels out in the future. Oftentimes, losses exist only on paper but other times, it can be a red flag. There are key fundamentals of Phathom Pharmaceuticals which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Phathom Pharmaceuticals, take a look at Phathom Pharmaceuticals' company page on Simply Wall St. We've also compiled a list of pertinent factors you should further examine: Valuation: What is Phathom Pharmaceuticals worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Phathom Pharmaceuticals is currently mispriced by the market. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Phathom Pharmaceuticals's board and the CEO's background. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here. — Investing narratives with Fair Values A case for TSXV:USA to reach USD $5.00 - $9.00 (CAD $7.30–$12.29) by 2029. By Agricola – Community Contributor Fair Value Estimated: CA$12.29 · 0.9% Overvalued DLocal's Future Growth Fueled by 35% Revenue and Profit Margin Boosts By WynnLevi – Community Contributor Fair Value Estimated: $195.39 · 0.9% Overvalued Historically Cheap, but the Margin of Safety Is Still Thin By Mandelman – Community Contributor Fair Value Estimated: SEK232.58 · 0.1% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
40 minutes ago
- Yahoo
Here's Why Boston Beer Co (SAM) Traded Down in Q1
Longleaf Partners, managed by Southeastern Asset Management, released its 'Small-Cap Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 1.50% in the first quarter, compared to the Russell 3000's -4.72% return and the Russell 2000's -9.48% decline. The portfolio performed well in a difficult quarter for small-cap stocks. For more information on the fund's best picks in 2025, please check its top five holdings. In its first-quarter 2025 investor letter, Longleaf Partners Small-Cap Fund highlighted stocks such as The Boston Beer Company, Inc. (NYSE:SAM). The Boston Beer Company, Inc. (NYSE:SAM) is a beverage company that engages in the production and distribution of alcoholic beverages. The one-month return of The Boston Beer Company, Inc. (NYSE:SAM) was -18.62%, and its shares lost 38.68% of their value over the last 52 weeks. On June 26, 2025, The Boston Beer Company, Inc. (NYSE:SAM) stock closed at $187.06 per share, with a market capitalization of $2.085 billion. Longleaf Partners Small-Cap Fund stated the following regarding The Boston Beer Company, Inc. (NYSE:SAM) in its Q1 2025 investor letter: "The Boston Beer Company, Inc. (NYSE:SAM) – US beverage company Boston Beer detracted in the quarter. The stock price has been under pressure due to macro concerns around declining alcohol consumption trends, combined with concerns on the Truly brand's continued declines and overall company margins. Both we and the company believe these headwinds can be overcome, and the company has multiple drivers to grow in the next twelve months. Management is taking action to increase value per share in the meantime by being one of our larger share repurchasers in the portfolio currently. Expectations for growth have been reset to a flattish level, and from this lower base, we remain optimistic in the long-term opportunity." A closeup shot of a beer tap pouring a golden lager. The Boston Beer Company, Inc. (NYSE:SAM) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 32 hedge fund portfolios held The Boston Beer Company, Inc. (NYSE:SAM) at the end of the first quarter, which was 29 in the previous quarter. While we acknowledge the potential of The Boston Beer Company, Inc. (NYSE:SAM) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered The Boston Beer Company, Inc. (NYSE:SAM) and shared the list of best alcohol stocks to buy according to billionaires. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of NYSE:SAM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.
